Health Canada approved Boey for the temporary improvement of moderate to severe glabellar lines, expanding Allergan Aesthetics' regulated product portfolio in Canada. The decision is a modest positive for AbbVie’s aesthetics unit, though the article provides no sales, pricing, or launch timing details. Market impact should be limited because this is a routine regulatory approval for a cosmetic indication.
Health Canada approved Boey for the temporary improvement of moderate to severe glabellar lines, expanding Allergan Aesthetics' regulated product portfolio in Canada. The decision is a modest positive for AbbVie’s aesthetics unit, though the article provides no sales, pricing, or launch timing details. Market impact should be limited because this is a routine regulatory approval for a cosmetic indication.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
